Back

Nation-wide use of guideline-directed medical therapies in heart failure across the ejection fraction range: The HECMOS study

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy 6 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ioannis Leontsinis

Hippokration General Hospital, Athens (Greece)

4 More presentations in this session

Presentation thumbnail
What factors are associated with myocardial recovery following admission for acute heart failure? Study in patients with de novo diagnosis and reduced left ventricular ejection fraction
Mr V. Donoso (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
SGLT2i treatment at the beginning of real time exposure in a HFrEF population
Associate Professor V. Vintila (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
The daily challenges to patients posed by diuretic therapy; what they are and what do patients do?
Doctor G. Bruno (Limerick, IE)
Abstract Slides Video
Presentation thumbnail
CA125 outperforms NT-proBNP in the prediction of maximum aerobic capacity in heart failure with preserved ejection fraction and cardiorenal syndrome
Mr G. Nunez Marin (Valencia, ES)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy 6

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Real-life management of heart failure: evaluation of medication optimisation in different phenotypes.
thumbnail
Congress Presentation
2021 ESC Guidelines on HF recommendations in daily practice: a survey results. A clinical scientific statement of the Heart Failure Association of the ESC and the Council for Cardiology Practice
thumbnail
Congress Presentation
Heart failure temporal mortality rates during the last two decades in Greece

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources